O	0	9	Improving
O	10	18	decision
O	19	25	making
O	26	31	about
O	32	40	clinical
O	41	46	trial
O	47	60	participation
O	61	62	-
O	63	64	a
O	65	75	randomised
O	76	86	controlled
O	87	92	trial
O	93	95	of
O	96	97	a
B-intervention	98	106	decision
I-intervention	107	110	aid
O	111	114	for
O	115	120	women
O	121	132	considering
O	133	146	participation
O	147	149	in
O	150	153	the
O	154	158	IBIS
O	158	159	-
O	159	161	II
O	162	168	breast
O	169	175	cancer
O	176	186	prevention
O	187	192	trial
O	192	193	.

O	194	202	Decision
O	203	207	aids
O	208	211	may
O	212	219	improve
O	220	228	informed
O	229	236	consent
O	237	239	in
O	240	248	clinical
O	249	254	trial
O	255	266	recruitment
O	266	267	,
O	268	271	but
O	272	276	have
O	277	280	not
O	281	285	been
O	286	295	evaluated
O	296	298	in
O	299	303	this
O	304	311	context
O	311	312	.

O	313	317	This
O	318	323	study
O	324	336	investigated
O	337	344	whether
O	345	353	decision
O	354	358	aids
O	359	360	(
O	360	363	DAs
O	363	364	)
O	365	368	can
O	369	375	reduce
O	376	386	decisional
O	387	399	difficulties
O	400	405	among
O	406	411	women
O	412	423	considering
O	424	437	participation
O	438	440	in
O	441	444	the
O	445	458	International
O	459	465	Breast
O	466	472	Cancer
O	473	485	Intervention
O	486	491	Study
O	491	492	-
O	492	494	II
O	495	496	(
O	496	500	IBIS
O	500	501	-
O	501	503	II
O	503	504	)
O	505	510	trial
O	510	511	.

O	512	515	The
O	516	520	IBIS
O	520	521	-
O	521	523	II
O	524	529	trial
O	530	542	investigated
O	543	549	breast
O	550	556	cancer
O	557	567	prevention
O	568	572	with
O	573	584	anastrazole
O	585	587	in
O	588	591	two
O	592	599	cohorts
O	599	600	:
B-eligibility	601	606	women
I-eligibility	607	611	with
I-eligibility	612	621	increased
I-eligibility	622	626	risk
I-eligibility	627	628	(
I-eligibility	628	638	Prevention
I-eligibility	638	639	)
I-eligibility	639	640	,
I-eligibility	641	644	and
I-eligibility	645	650	women
I-eligibility	651	658	treated
I-eligibility	659	662	for
I-eligibility	663	669	ductal
I-eligibility	670	679	carcinoma
I-eligibility	680	682	in
I-eligibility	683	687	situ
I-eligibility	688	689	(
I-eligibility	689	693	DCIS
I-eligibility	693	694	)
O	694	695	.

B-ethinicity	696	705	Australia
O	705	706	,
B-ethinicity	707	710	New
I-ethinicity	711	718	Zealand
O	719	722	and
B-ethinicity	723	729	United
I-ethinicity	730	737	Kingdom
O	738	750	participants
O	751	755	were
O	756	766	randomised
O	767	769	to
O	770	777	receive
O	778	779	a
O	780	782	DA
O	783	784	(
O	784	786	DA
O	787	792	group
O	792	793	)
O	794	796	or
B-control	797	805	standard
I-control	806	811	trial
I-control	812	819	consent
I-control	820	829	materials
I-control	830	831	(
I-control	831	838	control
I-control	839	844	group
I-control	844	845	)
O	845	846	.

O	847	861	Questionnaires
O	862	866	were
O	867	876	completed
O	877	882	after
O	883	891	deciding
O	892	897	about
O	898	911	participation
O	912	914	in
O	915	919	IBIS
O	919	920	-
O	920	922	II
O	923	924	(
O	924	928	post
O	929	937	decision
O	937	938	)
O	939	942	and
O	943	944	3
O	945	951	months
O	952	957	later
O	958	959	(
O	959	965	follow
O	965	966	-
O	966	968	up
O	968	969	)
O	969	970	.

O	971	975	Data
O	976	980	from
B-total-participants	981	984	112
O	985	995	Prevention
O	996	999	and
B-total-participants	1000	1002	34
O	1003	1007	DCIS
O	1008	1020	participants
O	1021	1025	were
O	1026	1034	analysed
O	1035	1039	post
O	1040	1048	decision
O	1049	1050	(
B-intervention-participants	1050	1052	73
O	1053	1055	DA
O	1055	1056	;
B-control-participants	1057	1059	73
O	1060	1067	control
O	1067	1068	)
O	1068	1069	;
B-total-participants	1070	1072	95
O	1073	1083	Prevention
O	1084	1087	and
B-total-participants	1088	1090	24
O	1091	1095	DCIS
O	1096	1108	participants
O	1109	1113	were
O	1114	1122	analysed
O	1123	1125	at
O	1126	1132	follow
O	1132	1133	-
O	1133	1135	up
O	1136	1137	(
B-intervention-participants	1137	1139	58
O	1140	1142	DA
O	1142	1143	;
B-control-participants	1144	1146	61
O	1147	1154	control
O	1154	1155	)
O	1155	1156	.

O	1157	1162	There
O	1163	1166	was
O	1167	1169	no
O	1170	1176	effect
O	1177	1179	on
O	1180	1183	the
O	1184	1191	primary
O	1192	1199	outcome
O	1200	1202	of
B-outcome	1203	1213	decisional
I-outcome	1214	1222	conflict
O	1222	1223	.

O	1224	1227	The
O	1228	1232	DCIS
O	1232	1233	-
O	1233	1235	DA
O	1236	1241	group
O	1242	1245	had
O	1246	1252	higher
B-outcome	1253	1262	knowledge
I-outcome	1263	1267	post
I-outcome	1268	1276	decision
O	1276	1277	,
O	1278	1281	and
O	1282	1285	the
O	1286	1296	Prevention
O	1296	1297	-
O	1297	1299	DA
O	1300	1305	group
O	1306	1309	had
O	1310	1315	lower
B-outcome	1316	1326	decisional
I-outcome	1327	1333	regret
O	1334	1336	at
O	1337	1343	follow
O	1343	1344	-
O	1344	1346	up
O	1346	1347	.

O	1348	1352	This
O	1353	1356	was
O	1357	1360	the
O	1361	1366	first
O	1367	1372	study
O	1373	1375	to
O	1376	1384	evaluate
O	1385	1386	a
O	1387	1389	DA
O	1390	1392	in
O	1393	1396	the
O	1397	1405	clinical
O	1406	1411	trial
O	1412	1419	setting
O	1419	1420	.

O	1421	1424	The
O	1425	1432	results
O	1433	1440	suggest
O	1441	1444	DAs
O	1445	1448	can
O	1449	1460	potentially
O	1461	1469	increase
O	1470	1479	knowledge
O	1480	1483	and
O	1484	1490	reduce
O	1491	1501	decisional
O	1502	1508	regret
O	1509	1514	about
O	1515	1523	clinical
O	1524	1529	trial
O	1530	1543	participation
O	1543	1544	.
